Literature DB >> 7976808

Modulation of the intracellular and H3-histamine receptors and chemically-induced seizures in mice.

G Sturman1, P Freeman, H M Meade, N A Seeley.   

Abstract

Central histaminergic modulation of H1 rather than H2-receptors has been shown to modify epileptic activity. Compounds acting on the HIC- and H3-receptors were tested against chemically-induced seizures in mice. Compounds antagonising the microsomal and nuclear intracellular receptors (HIC) only modified seizures at doses where toxicity was observed. Antagonists of the histamine H3-receptor (thioperamide and burimamide) only potentiated the severity of clonic convulsions induced by picrotoxin, while impromidine (i.c.v.), an antagonist with H2-agonist activity, inhibited leptazol-induced seizures. The H3-agonist, (R)alpha-methylhistamine, potentiated chemically-induced seizures, but at lower doses there was slight inhibition.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7976808     DOI: 10.1007/BF02007771

Source DB:  PubMed          Journal:  Agents Actions        ISSN: 0065-4299


  4 in total

Review 1.  Histamine as an intracellular messenger.

Authors:  L J Brandes; F S LaBella; G B Glavin; F Paraskevas; S P Saxena; A McNicol; J M Gerrard
Journal:  Biochem Pharmacol       Date:  1990-10-15       Impact factor: 5.858

2.  The toxic effects of antihistaminic drugs.

Authors:  J B WYNGAARDEN; M H SEEVERS
Journal:  J Am Med Assoc       Date:  1951-02-03

Review 3.  Histamine H3 ligands: just pharmacological tools or potential therapeutic agents?

Authors:  H Timmerman
Journal:  J Med Chem       Date:  1990-01       Impact factor: 7.446

4.  Is histamine an anticonvulsive inhibitory transmitter?

Authors:  L Tuomisto; U Tacke
Journal:  Neuropharmacology       Date:  1986-08       Impact factor: 5.250

  4 in total
  1 in total

Review 1.  Histamine H3 receptor antagonists in relation to epilepsy and neurodegeneration: a systemic consideration of recent progress and perspectives.

Authors:  M Bhowmik; R Khanam; D Vohora
Journal:  Br J Pharmacol       Date:  2012-12       Impact factor: 8.739

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.